Lake Street initiates MiMedx (MDXG.PK) at Buy.
The company is set to triple revenue for its wound care product EpiFix and double sales of AminoFix, its soft-tissue repair offering, analysts say.
The company also "has a foundation of strong intellectual property (100+ patents) and is led by an experienced management team with a history of successfully building and selling medical companies."
Ultimately, Lake Street thinks the company can top $400M in revenue and generate $100M in EBITDA "in the next four to five years."
Price target is $7.50.